Equities Analysts Offer Predictions for TSE:GUD Q4 Earnings

Knight Therapeutics Inc. (TSE:GUD) – Analysts at Raymond James issued their Q4 2025 earnings per share estimates for Knight Therapeutics in a research note issued to investors on Thursday, March 20th. Raymond James analyst M. Freeman forecasts that the company will post earnings per share of $0.01 for the quarter. The consensus estimate for Knight Therapeutics’ current full-year earnings is $0.10 per share. Raymond James also issued estimates for Knight Therapeutics’ Q1 2026 earnings at $0.00 EPS, Q2 2026 earnings at $0.01 EPS, Q3 2026 earnings at $0.02 EPS, Q4 2026 earnings at $0.02 EPS and FY2026 earnings at $0.04 EPS.

Separately, Research Capitl upgraded shares of Knight Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 11th.

Knight Therapeutics Price Performance

Shares of GUD stock opened at C$5.97 on Monday. Knight Therapeutics has a fifty-two week low of C$5.09 and a fifty-two week high of C$6.45. The company has a debt-to-equity ratio of 7.52, a quick ratio of 1.79 and a current ratio of 3.36. The firm has a market capitalization of C$603.87 million, a price-to-earnings ratio of -19.93, a PEG ratio of -1,013.50 and a beta of 0.50. The stock’s 50-day simple moving average is C$5.69 and its 200-day simple moving average is C$5.58.

Insider Buying and Selling

In other Knight Therapeutics news, insider Sime Armoyan purchased 17,600 shares of the business’s stock in a transaction that occurred on Tuesday, March 4th. The shares were bought at an average price of C$5.48 per share, for a total transaction of C$96,488.48. Insiders sold 3,143,300 shares of company stock worth $19,733,740 in the last 90 days. Insiders own 45.62% of the company’s stock.

Knight Therapeutics Company Profile

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.